This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Phibro (PAHC) Down 10.9% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro (PAHC) Sales Impacted by Macro Concerns, FX Headwind
by Zacks Equity Research
The COVID-19 pandemic has adversely affected the international economic conditions and financial markets, leading to an economic downturn in many countries, in which Phibro (PAHC) operates.
Phibro (PAHC) Q4 Earnings Miss Estimates, Gross Margin Falls
by Zacks Equity Research
Robust performance across the Animal Health segment is encouraging for Phirbo (PAHC).
Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic (MDT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 8.11% and 1.71%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
Phibro's (PAHC) Sales Hurt by Rising Costs, FX Headwind
by Zacks Equity Research
Phibro (PAHC) input costs continue to be high as a result of sustained inflation.
Apyx Medical (APYX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of 8.33% and 4.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of 45.45% and 3.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.63% and 0.63%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Investors Should Retain Phibro (PAHC) for Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.
Phibro (PAHC) Q3 Earnings Miss Estimates, Gross Margin Up
by Zacks Equity Research
Higher domestic demand and higher average selling prices for dairy products and growth in the companion animal product drive Phibro's (PAHC) Q3 revenues.
Phibro Animal Health (PAHC) Q3 Earnings Lag Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of -12.12% and 0.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro (PAHC) Q2 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Growing uptake of MFAs, dairy products and vaccines contributed to Phibro's (PAHC) Q2 revenues.
Phibro Animal Health (PAHC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of 13.33% and 2.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Baxter International (BAX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Phibro Animal Health (PAHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Phibro (PAHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Phibro (PAHC) stock based on the movements in the options market lately.
Phibro (PAHC) Q1 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Phibro's (PAHC) growing uptake of MFAs, dairy products and vaccines buoys optimism.
Phibro Animal Health (PAHC) Misses Q1 Earnings Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of -19.23% and 3.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Greenbrook TMS Inc. (GBNH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Greenbrook TMS Inc. (GBNH) delivered earnings and revenue surprises of -131.82% and 14.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Phibro (PAHC) Down 18.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AdaptHealth Corp. (AHCO) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
AdaptHealth Corp. (AHCO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Phirbo (PAHC) Faces Rising Costs and Inflationary Pressure
by Zacks Equity Research
Price competition coming from cheap generic alternatives of a few Phirbo (PAHC) products is a deterrent.